Cargando…

1113. Ceftazidime retains in vivo efficacy against strains of Stenotrophomonas maltophilia for which traditional testing predicts resistance

BACKGROUND: Stenotrophomonas maltophilia is responsible for a growing number of nosocomial infections and is susceptible to a limited number of antibiotics. Recently the in vivo accuracy of conventional antibiotic resistance testing methods has been called into question. We sought to determine if th...

Descripción completa

Detalles Bibliográficos
Autores principales: Phillips, Matthew C, Lee, Bosul, Miller, Sarah, Yan, Jun, Maeusli, Marlene, She, Rosemary, Luna, Brian M, Spellberg, Brad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677325/
http://dx.doi.org/10.1093/ofid/ofad500.086
_version_ 1785150102990487552
author Phillips, Matthew C
Lee, Bosul
Miller, Sarah
Yan, Jun
Maeusli, Marlene
She, Rosemary
Luna, Brian M
Spellberg, Brad
author_facet Phillips, Matthew C
Lee, Bosul
Miller, Sarah
Yan, Jun
Maeusli, Marlene
She, Rosemary
Luna, Brian M
Spellberg, Brad
author_sort Phillips, Matthew C
collection PubMed
description BACKGROUND: Stenotrophomonas maltophilia is responsible for a growing number of nosocomial infections and is susceptible to a limited number of antibiotics. Recently the in vivo accuracy of conventional antibiotic resistance testing methods has been called into question. We sought to determine if there were efficacious antibiotics against S maltophilia that would be overlooked due to specious in vivo resistance determined by traditional methods. METHODS: Antibiotic resistance testing was performed utilizing conventional and nutrient-limited media. Antibiotics with discordant minimum inhibitory concentrations (MICs) between the two media were selected for further experimentation. Metal ions were supplemented back into the nutrient-limited media to establish possible mechanisms. In vivo corroborations of in vitro MICs were done utilizing two infection models, Galleria mellonella and a neutropenic mouse oral aspiration pneumonia model. RESULTS: S. maltophilia MICs were significantly lower for ceftazidime in nutritionally deficient than conventional media, resulting in a high percentage of strains determined resistant in traditional media being determined susceptible in nutritionally-deficient media. The addition of zinc and manganese to the deficient media abrogated this difference. Ceftazidime protected both G. mellonella and neutropenic mice against lethal infection caused by S. maltophilia that was predicted resistant in traditional media but sensitive in nutrient-deficient media. S. Trophomonas more susceptible to ceftazidime (CAZ) but not aztreonam (ATM) and cefepime (FEP) in biologically relevant media [Figure: see text] MICs were determined in MHII or RPMI-1640 media against an expanded panel of S. maltophilia clinical isolates. A) Comparing within drugs, there was a significant difference for MICs determined in MHII as compared to RPMI-1640 (p=6.89E-9 (ATM), 1.47E-11 (FEP), and 3.53E-13 (CAZ), Mann-Whitney). B) Axes represent different growth conditions. The dashed lines indicate the susceptible breakpoints. Everything to the left of the vertical line is predicted to be susceptible in MHII and everything below the horizontal line is predicted to be susceptible in RPMI-1640. Right lower quadrant represents isolates resistant in MHII but susceptible in RPMI-1640. CAZ was significantly different from ATM (Mann-Whitney, p=7.47E-6) and FEP (Mann-Whitney, p=7.41E-6). There was no significant difference between the ATM and FEP groups. All MICs determined for CAZ in RPMI-1640 were less than 8 mg/L and represent a susceptible breakpoint interpretation. CAZ efficacy in a murine infection model [Figure: see text] Dosing and dosing intervals for a human equivalent dosing strategy of 100 mg/kg were done as previously described. The dosing interval was kept constant, and doses administered were proportionally scaled up for the 300 mg/kg and 1000 mg/kg treatment groups. CONCLUSION: Ceftazidime may remain a viable therapeutic option for patients with S. maltophilia infection caused by strains predicted to be resistant by traditional susceptibility testing. Sequestration of trace metals in the host environment may prevent S. maltophilia beta-lactamase activity against ceftazidime. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-10677325
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106773252023-11-27 1113. Ceftazidime retains in vivo efficacy against strains of Stenotrophomonas maltophilia for which traditional testing predicts resistance Phillips, Matthew C Lee, Bosul Miller, Sarah Yan, Jun Maeusli, Marlene She, Rosemary Luna, Brian M Spellberg, Brad Open Forum Infect Dis Abstract BACKGROUND: Stenotrophomonas maltophilia is responsible for a growing number of nosocomial infections and is susceptible to a limited number of antibiotics. Recently the in vivo accuracy of conventional antibiotic resistance testing methods has been called into question. We sought to determine if there were efficacious antibiotics against S maltophilia that would be overlooked due to specious in vivo resistance determined by traditional methods. METHODS: Antibiotic resistance testing was performed utilizing conventional and nutrient-limited media. Antibiotics with discordant minimum inhibitory concentrations (MICs) between the two media were selected for further experimentation. Metal ions were supplemented back into the nutrient-limited media to establish possible mechanisms. In vivo corroborations of in vitro MICs were done utilizing two infection models, Galleria mellonella and a neutropenic mouse oral aspiration pneumonia model. RESULTS: S. maltophilia MICs were significantly lower for ceftazidime in nutritionally deficient than conventional media, resulting in a high percentage of strains determined resistant in traditional media being determined susceptible in nutritionally-deficient media. The addition of zinc and manganese to the deficient media abrogated this difference. Ceftazidime protected both G. mellonella and neutropenic mice against lethal infection caused by S. maltophilia that was predicted resistant in traditional media but sensitive in nutrient-deficient media. S. Trophomonas more susceptible to ceftazidime (CAZ) but not aztreonam (ATM) and cefepime (FEP) in biologically relevant media [Figure: see text] MICs were determined in MHII or RPMI-1640 media against an expanded panel of S. maltophilia clinical isolates. A) Comparing within drugs, there was a significant difference for MICs determined in MHII as compared to RPMI-1640 (p=6.89E-9 (ATM), 1.47E-11 (FEP), and 3.53E-13 (CAZ), Mann-Whitney). B) Axes represent different growth conditions. The dashed lines indicate the susceptible breakpoints. Everything to the left of the vertical line is predicted to be susceptible in MHII and everything below the horizontal line is predicted to be susceptible in RPMI-1640. Right lower quadrant represents isolates resistant in MHII but susceptible in RPMI-1640. CAZ was significantly different from ATM (Mann-Whitney, p=7.47E-6) and FEP (Mann-Whitney, p=7.41E-6). There was no significant difference between the ATM and FEP groups. All MICs determined for CAZ in RPMI-1640 were less than 8 mg/L and represent a susceptible breakpoint interpretation. CAZ efficacy in a murine infection model [Figure: see text] Dosing and dosing intervals for a human equivalent dosing strategy of 100 mg/kg were done as previously described. The dosing interval was kept constant, and doses administered were proportionally scaled up for the 300 mg/kg and 1000 mg/kg treatment groups. CONCLUSION: Ceftazidime may remain a viable therapeutic option for patients with S. maltophilia infection caused by strains predicted to be resistant by traditional susceptibility testing. Sequestration of trace metals in the host environment may prevent S. maltophilia beta-lactamase activity against ceftazidime. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2023-11-27 /pmc/articles/PMC10677325/ http://dx.doi.org/10.1093/ofid/ofad500.086 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Phillips, Matthew C
Lee, Bosul
Miller, Sarah
Yan, Jun
Maeusli, Marlene
She, Rosemary
Luna, Brian M
Spellberg, Brad
1113. Ceftazidime retains in vivo efficacy against strains of Stenotrophomonas maltophilia for which traditional testing predicts resistance
title 1113. Ceftazidime retains in vivo efficacy against strains of Stenotrophomonas maltophilia for which traditional testing predicts resistance
title_full 1113. Ceftazidime retains in vivo efficacy against strains of Stenotrophomonas maltophilia for which traditional testing predicts resistance
title_fullStr 1113. Ceftazidime retains in vivo efficacy against strains of Stenotrophomonas maltophilia for which traditional testing predicts resistance
title_full_unstemmed 1113. Ceftazidime retains in vivo efficacy against strains of Stenotrophomonas maltophilia for which traditional testing predicts resistance
title_short 1113. Ceftazidime retains in vivo efficacy against strains of Stenotrophomonas maltophilia for which traditional testing predicts resistance
title_sort 1113. ceftazidime retains in vivo efficacy against strains of stenotrophomonas maltophilia for which traditional testing predicts resistance
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677325/
http://dx.doi.org/10.1093/ofid/ofad500.086
work_keys_str_mv AT phillipsmatthewc 1113ceftazidimeretainsinvivoefficacyagainststrainsofstenotrophomonasmaltophiliaforwhichtraditionaltestingpredictsresistance
AT leebosul 1113ceftazidimeretainsinvivoefficacyagainststrainsofstenotrophomonasmaltophiliaforwhichtraditionaltestingpredictsresistance
AT millersarah 1113ceftazidimeretainsinvivoefficacyagainststrainsofstenotrophomonasmaltophiliaforwhichtraditionaltestingpredictsresistance
AT yanjun 1113ceftazidimeretainsinvivoefficacyagainststrainsofstenotrophomonasmaltophiliaforwhichtraditionaltestingpredictsresistance
AT maeuslimarlene 1113ceftazidimeretainsinvivoefficacyagainststrainsofstenotrophomonasmaltophiliaforwhichtraditionaltestingpredictsresistance
AT sherosemary 1113ceftazidimeretainsinvivoefficacyagainststrainsofstenotrophomonasmaltophiliaforwhichtraditionaltestingpredictsresistance
AT lunabrianm 1113ceftazidimeretainsinvivoefficacyagainststrainsofstenotrophomonasmaltophiliaforwhichtraditionaltestingpredictsresistance
AT spellbergbrad 1113ceftazidimeretainsinvivoefficacyagainststrainsofstenotrophomonasmaltophiliaforwhichtraditionaltestingpredictsresistance